NL-OMON22299招募中不适用

PHASE I-II STUDY OF GEMCITABINE (GCB) AND VALPROIC ACID(VPA) PLUS VALGANCICLOVIR(GCV) IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA(NPC).

sponsor:ZonMWperfomers: the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

Feng, W., G. Hong, H. Delecluse, and S. Kenney. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J.Virol. 2004; p1893-902.
2. Feng, W. and S. Kenney. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006; p8762-69.
3. Braakhuis, B., v. H. Ruiz, V, M. Welters, and G. Peters. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur.J.Cancer 1995; p2335-404.
Tao, Q. and A. Chan. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert.Rev.Mol.Med. 2007;p1-24.

•1. Patient has histological confirmed residual, recurrent or metastatic nasopharyngeal carcinoma that has failed conventional curative treatments and deemed incurable, or patient refuses further treatment with conventional methods because of associated morbidity/mortality or private reasons;
•2. Confirmed EBV positive NPC;

•1. Active infection (infection requiring IV antibiotics), including active tuberculosis, and known and declared HIV;
•2. Pregnancy (absence confirmed by serum or urine β-HCG test) or lactation period;

发起方

sponsor:ZonMWperfomers: the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital